Lupin jumps on getting nod to acquire portfolio of brands of Anglo-French Drugs & Industries
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Lupin is currently trading at Rs. 952.75, up by 10.20 points or 1.08% from its previous closing of Rs. 942.55 on the BSE.
The scrip opened at Rs. 942.00 and has touched a high and low of Rs. 961.50 and Rs. 936.80 respectively. So far 118490 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1267.50 on 02-Jun-2021 and a 52 week low of Rs. 854.00 on 20-Dec-2021.
Last one week high and low of the scrip stood at Rs. 971.30 and Rs. 935.30 respectively. The current market cap of the company is Rs. 43300.86 crore.
The promoters holding in the company stood at 46.81%, while Institutions and Non-Institutions held 40.39% and 12.79% respectively.
Lupin has received an approval for the acquisition of a portfolio of brands (including all rights and interests associated with such products) of Anglo-French Drugs & Industries and its associates (subject to approval of their shareholders). The acquisition would enable addition of established brands with high recall amongst healthcare professionals, especially in the Vitamins, Minerals and Supplements category. The Board of Directors of the company at its meeting held on January 17, 2022, approved the same.
